Skip to main content
Erschienen in: CardioVasc 3/2015

10.06.2015 | Schwerpunkt_Adipositas

Individuell dosieren

Besonderheiten der Pharmakotherapie adipöser Patienten

verfasst von: Dr. med. Marcus May, Stefan Engeli

Erschienen in: CardioVasc | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Interaktionen zwischen Körpergewicht und Arzneimitteltherapie sind vielfältig. Einerseits wirken sich viele Medikamente nachteilig auf den Stoffwechsel aus, andererseits ist bei Adipositas, insbesondere bei Arzneimitteln mit einer kleinen therapeutischen Breite, eine Dosisanpassung notwendig. Die veränderte Körperzusammensetzung, insbesondere das stark vermehrte Fettgewebe, veränderter regionaler Blutfluss sowie Bindung an Plasmaeiweiße und Gewebestrukturen sind Einflussfaktoren auf pharmakokinetische Eigenschaften von Medikamenten. Darüber hinaus ist bei Adipösen der Metabolismus über Cytochrom-P450-Enzyme verändert und eine eingeschränkte Nierenfunktion häufig. Nach bariatrischer Chirurgie und darauffolgender massiver Gewichtsreduktion ist aufgrund der anatomischen und physiologischen Änderungen mit Unterschieden in Pharmakokinetik und -dynamik zu rechnen. Insgesamt liegen nur unzureichende Daten zur Dosisanpassung bei Adipositas und insbesondere nach bariatrischer Chriurgie vor. Wichtige grundsätzliche Annahmen für die Wahl einer individuellen pharmakotherapeutischen Behandlung adipöser Patienten werden hier dargestellt und wichtige Medikamente exemplarisch beschrieben.
Literatur
1.
Zurück zum Zitat Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87PubMedCrossRef Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87PubMedCrossRef
2.
Zurück zum Zitat Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis. 2010;29(2):233–40PubMedCrossRef Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis. 2010;29(2):233–40PubMedCrossRef
3.
Zurück zum Zitat Jacques KA, Erstad BL. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm. 2010;67(22):1948–50PubMedCrossRef Jacques KA, Erstad BL. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm. 2010;67(22):1948–50PubMedCrossRef
4.
Zurück zum Zitat Jain R, Chung SM, Jain L et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77–89PubMedCrossRef Jain R, Chung SM, Jain L et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77–89PubMedCrossRef
5.
Zurück zum Zitat Must A, Spadano J, Coakley EH et al. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9 Must A, Spadano J, Coakley EH et al. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9
6.
Zurück zum Zitat Roach RE, Lijfering WM, van Hylckama Vlieg A et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122(26):4264–9PubMedCrossRef Roach RE, Lijfering WM, van Hylckama Vlieg A et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122(26):4264–9PubMedCrossRef
7.
Zurück zum Zitat Badimon L, Hernández Vera R, Padró T, Vilahur G. Antithrombotic therapy in obesity. Thromb Haemost. 2013;110(4):681–8.PubMedCrossRef Badimon L, Hernández Vera R, Padró T, Vilahur G. Antithrombotic therapy in obesity. Thromb Haemost. 2013;110(4):681–8.PubMedCrossRef
8.
Zurück zum Zitat Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet. 1993;25(2):103–14PubMedCrossRef Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet. 1993;25(2):103–14PubMedCrossRef
9.
Zurück zum Zitat Lesser GT, Deutsch S. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol. 1967;23(5):621–30PubMed Lesser GT, Deutsch S. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol. 1967;23(5):621–30PubMed
10.
Zurück zum Zitat Prather RD, Tu TG, Rolf CN, Gorsline J. Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men. J Clin Pharmacol. 1993;33(7):644–9PubMedCrossRef Prather RD, Tu TG, Rolf CN, Gorsline J. Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men. J Clin Pharmacol. 1993;33(7):644–9PubMedCrossRef
11.
Zurück zum Zitat Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care. 1995;18(7):986–91PubMedCrossRef Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care. 1995;18(7):986–91PubMedCrossRef
12.
Zurück zum Zitat Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308–18PubMedCrossRef Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308–18PubMedCrossRef
13.
Zurück zum Zitat Hainer JW, Barrett JS, Assaid CA et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87(5):817–23PubMed Hainer JW, Barrett JS, Assaid CA et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87(5):817–23PubMed
14.
Zurück zum Zitat Shah DK, Missmer SA, Correia KF, Ginsburg ES. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal weight women. J Clin Endocrinol Metab. 2014;99(4):1314–21PubMedCentralPubMedCrossRef Shah DK, Missmer SA, Correia KF, Ginsburg ES. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal weight women. J Clin Endocrinol Metab. 2014;99(4):1314–21PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Gagnon-Auger M, du Souich P, Baillargeon JP et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33(12):2502.PubMedCentralPubMedCrossRef Gagnon-Auger M, du Souich P, Baillargeon JP et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33(12):2502.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Johnstone J, Hobbins S, Parekh D, O’Hickey S. Excess subcutaneous tissue may preclude intramuscular delivery when using epinephrine autoinjectors in patients with anaphylaxis. Allergy. 2015 Feb 13. doi: 10.1111/all.12595 Johnstone J, Hobbins S, Parekh D, O’Hickey S. Excess subcutaneous tissue may preclude intramuscular delivery when using epinephrine autoinjectors in patients with anaphylaxis. Allergy. 2015 Feb 13. doi: 10.1111/all.12595
17.
Zurück zum Zitat Forbes GB, Welle SL. Lean body mass in obesity. Int J Obes. 1983;7(2):99–107PubMed Forbes GB, Welle SL. Lean body mass in obesity. Int J Obes. 1983;7(2):99–107PubMed
18.
Zurück zum Zitat Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs: Pharmacokinetic consequences. Clin Pharmacokinet. 1992;23(6):449–8PubMedCrossRef Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs: Pharmacokinetic consequences. Clin Pharmacokinet. 1992;23(6):449–8PubMedCrossRef
19.
Zurück zum Zitat Di Minno MN, Lupoli R, Di Minno A et al. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials. Ann Med. 2015;47(1):61–8PubMedCrossRef Di Minno MN, Lupoli R, Di Minno A et al. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials. Ann Med. 2015;47(1):61–8PubMedCrossRef
20.
Zurück zum Zitat Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. Clin Pharmacol Ther. 1984;36(6):824–31PubMedCrossRef Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. Clin Pharmacol Ther. 1984;36(6):824–31PubMedCrossRef
22.
Zurück zum Zitat Brill MJE, Diepstraten J, Van Rongen A et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304PubMedCrossRef Brill MJE, Diepstraten J, Van Rongen A et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304PubMedCrossRef
23.
Zurück zum Zitat Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther. 1982;31(6):783–90PubMedCrossRef Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther. 1982;31(6):783–90PubMedCrossRef
24.
Zurück zum Zitat Murray M. Altered CYP expression and function in response to dietary factors: Potential roles in disease pathogenesis. Curr Drug Metab. 2006;7(1):67–81PubMedCrossRef Murray M. Altered CYP expression and function in response to dietary factors: Potential roles in disease pathogenesis. Curr Drug Metab. 2006;7(1):67–81PubMedCrossRef
25.
Zurück zum Zitat Kobori T, Harada S, Nakamoto K, Tokuyama S. Functional alterations of intestinal P-glycoprotein under diabetic conditions. Biol Pharm Bull. 2013;36(9):1381–90PubMedCrossRef Kobori T, Harada S, Nakamoto K, Tokuyama S. Functional alterations of intestinal P-glycoprotein under diabetic conditions. Biol Pharm Bull. 2013;36(9):1381–90PubMedCrossRef
26.
Zurück zum Zitat Hall JE, Brands MW, Dixon WN, Smith MJ Jr. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension. 1993;22(3):292–9PubMedCrossRef Hall JE, Brands MW, Dixon WN, Smith MJ Jr. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension. 1993;22(3):292–9PubMedCrossRef
27.
Zurück zum Zitat Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97(1):59-74 Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97(1):59-74
28.
Zurück zum Zitat Pai MP. Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug Dosing. Adv Chron Kidney Dis. 2010;17(5):e53–e62CrossRef Pai MP. Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug Dosing. Adv Chron Kidney Dis. 2010;17(5):e53–e62CrossRef
29.
Zurück zum Zitat Nelson WK, Formica RN,Jr, Cooper DL et al. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. J Oncol Pharm Pract. 2012;18(3):323–32PubMedCrossRef Nelson WK, Formica RN,Jr, Cooper DL et al. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. J Oncol Pharm Pract. 2012;18(3):323–32PubMedCrossRef
30.
Zurück zum Zitat Geier A, Dietrich CG, Grote T et al. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol. 2005;43(6):1021–30PubMedCrossRef Geier A, Dietrich CG, Grote T et al. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol. 2005;43(6):1021–30PubMedCrossRef
31.
Zurück zum Zitat Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100(7):395–404PubMedCrossRef Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100(7):395–404PubMedCrossRef
33.
Zurück zum Zitat Hasnain M, Vieweg WV. Weight considerations in psychotropic drug prescribing and switching. Postgrad Med. 2013;125(5):117–29PubMedCrossRef Hasnain M, Vieweg WV. Weight considerations in psychotropic drug prescribing and switching. Postgrad Med. 2013;125(5):117–29PubMedCrossRef
34.
Zurück zum Zitat Day DS, Gozansky WS, Van Pelt RE et al. Sex hormone suppression reduces resting energy expenditure and ta-adrenergic support of resting energy expenditure. J Clin Endocrinol Metab. 2005;90(6):3312–7 Day DS, Gozansky WS, Van Pelt RE et al. Sex hormone suppression reduces resting energy expenditure and ta-adrenergic support of resting energy expenditure. J Clin Endocrinol Metab. 2005;90(6):3312–7
35.
Zurück zum Zitat Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol. 2004;103(2):359–73PubMedCrossRef Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol. 2004;103(2):359–73PubMedCrossRef
36.
Zurück zum Zitat Espeland MA, Stefanick ML, Kritz-Silverstein D et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. J Clin Endocrinol Metab. 1997;82(5):1549–56PubMed Espeland MA, Stefanick ML, Kritz-Silverstein D et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. J Clin Endocrinol Metab. 1997;82(5):1549–56PubMed
37.
Zurück zum Zitat Sugiyama T, Tsugawa Y, Tseng CH et al. Different Time Trends of Caloric and Fat Intake Between Statin Users and Nonusers Among US Adults: Gluttony in the Time of Statins? JAMA Intern Med. 2014;174(7):1038–45PubMedCrossRef Sugiyama T, Tsugawa Y, Tseng CH et al. Different Time Trends of Caloric and Fat Intake Between Statin Users and Nonusers Among US Adults: Gluttony in the Time of Statins? JAMA Intern Med. 2014;174(7):1038–45PubMedCrossRef
38.
Zurück zum Zitat Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA. 2005;294(15):1909–17PubMedCrossRef Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA. 2005;294(15):1909–17PubMedCrossRef
39.
Zurück zum Zitat Tandra S, Chalasani N, Jones DR et al. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262–9PubMedCrossRef Tandra S, Chalasani N, Jones DR et al. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262–9PubMedCrossRef
40.
Zurück zum Zitat Yska JP, Van Der Linde S, Tapper VV et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obesity Surg. 2013;23(6):819–25CrossRef Yska JP, Van Der Linde S, Tapper VV et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obesity Surg. 2013;23(6):819–25CrossRef
41.
Zurück zum Zitat Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34PubMedCrossRef Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34PubMedCrossRef
42.
Zurück zum Zitat Schauer PR, Ikramuddin S, Hamad G et al. Laparoscopic gastric bypass surgery: Current technique. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A. 2003;13(4):229–39PubMedCrossRef Schauer PR, Ikramuddin S, Hamad G et al. Laparoscopic gastric bypass surgery: Current technique. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A. 2003;13(4):229–39PubMedCrossRef
43.
Zurück zum Zitat Bloomberg RD, Fleishman A, Nalle JE et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15(2):145–54CrossRef Bloomberg RD, Fleishman A, Nalle JE et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15(2):145–54CrossRef
44.
Zurück zum Zitat Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50PubMedCrossRef Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50PubMedCrossRef
45.
Zurück zum Zitat Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63(19):1852–7PubMedCrossRef Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63(19):1852–7PubMedCrossRef
46.
Zurück zum Zitat Titus R, Kastenmeier A, Otterson MF. Consequences of gastrointestinal surgery on drug absorption. Nutr Clin Prac. 2013;28(4):429–36CrossRef Titus R, Kastenmeier A, Otterson MF. Consequences of gastrointestinal surgery on drug absorption. Nutr Clin Prac. 2013;28(4):429–36CrossRef
47.
Zurück zum Zitat Smet JD, Van Bocxlaer J, Boussery K. The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs. J Clin Pharmacol. 2013;53(4):361–76PubMedCrossRef Smet JD, Van Bocxlaer J, Boussery K. The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs. J Clin Pharmacol. 2013;53(4):361–76PubMedCrossRef
48.
Zurück zum Zitat Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46(1):130–6PubMedCrossRef Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46(1):130–6PubMedCrossRef
49.
Zurück zum Zitat Mitchell JE, Crosby R, de Zwaan M et al. Possible risk factors for increased suicide following bariatric surgery. Obesity (Silver Spring). 2013;21(4):665–72CrossRef Mitchell JE, Crosby R, de Zwaan M et al. Possible risk factors for increased suicide following bariatric surgery. Obesity (Silver Spring). 2013;21(4):665–72CrossRef
50.
Zurück zum Zitat Jakobsen GS, Skottheim IB, Sandbu R et al. Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin. Surg Endosc. 2013;27(6):2094–101PubMedCentralPubMedCrossRef Jakobsen GS, Skottheim IB, Sandbu R et al. Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin. Surg Endosc. 2013;27(6):2094–101PubMedCentralPubMedCrossRef
51.
Zurück zum Zitat Hamad GG, Helsel JC, Perel JM et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169(3):256–63PubMedCentralPubMedCrossRef Hamad GG, Helsel JC, Perel JM et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169(3):256–63PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat May M, Engeli S. Pharmakokinetische Besonderheiten bei adipösen Patienten. Adipositas 2014;8:89–94 May M, Engeli S. Pharmakokinetische Besonderheiten bei adipösen Patienten. Adipositas 2014;8:89–94
Metadaten
Titel
Individuell dosieren
Besonderheiten der Pharmakotherapie adipöser Patienten
verfasst von
Dr. med. Marcus May
Stefan Engeli
Publikationsdatum
10.06.2015
Verlag
Urban & Vogel
Erschienen in
CardioVasc / Ausgabe 3/2015
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI
https://doi.org/10.1007/s15027-015-0638-4

Weitere Artikel der Ausgabe 3/2015

CardioVasc 3/2015 Zur Ausgabe

Aktuell_ACC-Kongress

Moderne Stents oder Bypass?

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.